Chris Hafner
SpyGlass Pharma, Inc. · NuVasive
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chris Hafner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:18 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06120842 · Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic SolutionSpyGlass Pharma, Inc. · active not recruiting · Cataract, Glaucoma, Ocular Hypertension · study chair
- N/ANCT02717845 · CT Imaging Study for Knee Osteotomy (CISKO)North Cumbria University Hospitals NHS Trust · unknown · Bone Malalignment · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:18 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Open reduction and internal fixation of proximal humerus fractures using a proximal humeral locked plate: a prospective multicenter analysis.J Orthop Trauma · 2009324 citationsRCR 18.4
- 121 citationsRCR 3.3
- 113 citationsRCR 2.4
- Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity.J Allergy Clin Immunol · 202039 citationsRCR 2.5
- [Multimodal group therapy for the elderly with chronic pain: concept and results in a before and after comparison].Schmerz · 200818 citationsRCR 0.8
- Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies.J Eur Acad Dermatol Venereol · 202318 citationsRCR 1.5
- Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.J Eur Acad Dermatol Venereol · 201615 citationsRCR 0.5
- 15 citationsRCR 1.2
- Live stream of prehospital point-of-care ultrasound during cardiopulmonary resuscitation - A feasibility trial.Resuscitation · 20248 citationsRCR 1.6